NEW YORK, July 27, 2020 /PRNewswire/
-- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader
in developing innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, announced today that the
Company will hold a conference call to update shareholders on
financial results for the second quarter ended June 30, 2020, and provide a corporate update, at
8:00 a.m., Eastern Daylight Time
(EDT), on Wednesday, August 5
2020.
On the call, BrainStorm CEO Chaim
Lebovits will present a corporate update, including details
on the timeline for the data readout of the Company's Phase 3
pivotal trial studying the safety and efficacy of NurOwn® (MSC-NTF
cell) in people with ALS. In addition, Dr. Revital Aricha. Brainstorm's Vice President of
Research and Development, will provide an R&D update including
recently announced data from the Company's groundbreaking
preclinical study evaluating NurOwn-derived exosomes for the
treatment of COVID-19 ARDS.
Thereafter, senior management officers will join the call for a
Q&A session. Participants are encouraged to submit their
questions prior to the call by sending them
to: q@brainstorm-cell.com. Questions should be submitted
by 5:00 p.m. EDT, Monday, August 3, 2020.
Teleconference Details – BRAINSTORM CELL THERAPEUTICS 2Q
2020
The investment community may participate in the conference call
by dialing the following numbers:
Participant
Numbers:
|
Toll Free:
877-407-9205
International: 201-689-8054
|
Those interested in listening to the conference call live via
the internet may do so by visiting the "Investors & Media" page
of BrainStorm's website at www.ir.brainstorm-cell.com and
clicking on the conference call link.
Event
Link:
|
Webcast URL:
https://bit.ly/2DciAC9
|
Webcast Replay
Expiration:
|
Thursday, August 05,
2021
|
Those that wish to listen to the replay of the conference call
can do so by dialing the numbers below. The replay will be
available for 14 days.
Replay
Number:
|
Toll Free:
877-481-4010
International: 919-882-2331
Replay Passcode: 36017
|
Teleconference Replay
Expiration:
|
Wednesday, August 19,
2020
|
About NurOwn®
NurOwn (autologous MSC-NTF) cells represent a promising
investigational therapeutic approach to targeting disease pathways
important in neurodegenerative disorders. MSC-NTF cells are
produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors (NTFs). Autologous MSC-NTF cells can
effectively deliver multiple NTFs and immunomodulatory cytokines
directly to the site of damage to elicit a desired biological
effect and ultimately slow or stabilize disease progression.
BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous
MSC-NTF cells for the treatment of amyotrophic lateral sclerosis
(ALS). BrainStorm also recently received acceptance from
the U.S. Food and Drug Administration (FDA) to initiate a
Phase 2 open-label multicenter trial in progressive multiple
sclerosis (MS) and initiated enrollment in March 2019.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of
innovative autologous adult stem cell therapeutics for debilitating
neurodegenerative diseases. The Company holds the rights to
clinical development and commercialization of the NurOwn technology
platform used to produce autologous MSC-NTF cells through an
exclusive, worldwide licensing agreement. Autologous MSC-NTF cells
have received Orphan Drug status designation from the U.S.
Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) for the treatment of amyotrophic
lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3
pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at
six U.S. sites supported by a grant from
the California Institute for Regenerative Medicine (CIRM
CLIN2-0989). The pivotal study is intended to support a filing
for U.S. FDA approval of autologous MSC-NTF cells in ALS.
BrainStorm also recently received U.S. FDA clearance to
initiate a Phase 2 open-label multicenter trial in progressive
multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF
cells in patients with progressive MS (NCT03799718) started
enrollment in March 2019. For more information, visit the
company's website at www.brainstorm-cell.com.
Safe-Harbor Statement
Statements in this announcement other than historical data and
information, including statements regarding future clinical trial
enrollment and data, constitute "forward-looking statements" and
involve risks and uncertainties that could cause BrainStorm
Cell Therapeutics Inc.'s actual results to differ materially
from those stated or implied by such forward-looking statements.
Terms and phrases such as "may", "should", "would", "could",
"will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, BrainStorm's need to
raise additional capital, BrainStorm's ability to continue as a
going concern, regulatory approval of BrainStorm's NurOwn treatment
candidate, the success of BrainStorm's product development programs
and research, regulatory and personnel issues, development of a
global market for our services, the ability to secure and maintain
research institutions to conduct our clinical trials, the ability
to generate significant revenue, the ability of BrainStorm's NurOwn
treatment candidate to achieve broad acceptance as a treatment
option for ALS or other neurodegenerative diseases, BrainStorm's
ability to manufacture and commercialize the NurOwn treatment
candidate, obtaining patents that provide meaningful protection,
competition and market developments, BrainStorm's ability to
protect our intellectual property from infringement by third
parties, heath reform legislation, demand for our services,
currency exchange rates and product liability claims and
litigation,; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available
at http://www.sec.gov. These factors should be considered
carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
CONTACTS
Investor Relations:
Preetam
Shah, MBA, PhD
Chief Financial Officer
BrainStorm Cell Therapeutics Inc.
Phone: +1-862-397-1860
pshah@brainstorm-cell.com
Media:
Paul Tyahla
SmithSolve
Phone: +1-973-713-3768
Paul.tyahla@smithsolve.com
View original
content:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-announce-second-quarter-financial-results-and-provide-a-corporate-and-rd-update-301100141.html
SOURCE Brainstorm Cell Therapeutics Inc